Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Investment analysts at SunTrust Banks lifted their FY2017 EPS estimates for shares of Tetraphase Pharmaceuticals in a report issued on Thursday. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings of ($2.93) per share for the year, up from their previous estimate of ($2.97). SunTrust Banks also issued estimates for Tetraphase Pharmaceuticals’ Q4 2017 earnings at ($0.69) EPS, Q1 2018 earnings at ($0.61) EPS, Q2 2018 earnings at ($0.62) EPS, Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($2.31) EPS, FY2019 earnings at ($2.18) EPS, FY2020 earnings at ($0.95) EPS and FY2021 earnings at $0.35 EPS.

A number of other equities research analysts also recently commented on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Piper Jaffray Companies initiated coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price for the company. Finally, ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $15.15.

ILLEGAL ACTIVITY WARNING: “SunTrust Banks Weighs in on Tetraphase Pharmaceuticals, Inc.’s FY2017 Earnings (TTPH)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/08/suntrust-banks-weighs-in-on-tetraphase-pharmaceuticals-inc-s-fy2017-earnings-ttph.html.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.40 on Monday. Tetraphase Pharmaceuticals has a twelve month low of $3.39 and a twelve month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. The company’s revenue was up 355.6% compared to the same quarter last year.

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals in the third quarter valued at approximately $107,000. AXA acquired a new position in Tetraphase Pharmaceuticals in the second quarter valued at approximately $132,000. Citadel Advisors LLC lifted its holdings in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,496 shares during the period. Virtu KCG Holdings LLC acquired a new position in Tetraphase Pharmaceuticals in the second quarter valued at approximately $147,000. Finally, Voya Investment Management LLC lifted its holdings in Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the period. 42.68% of the stock is owned by institutional investors.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $5.86, for a total value of $41,928.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 33,405 shares of company stock valued at $199,691 over the last three months. 5.50% of the stock is currently owned by corporate insiders.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.